November 21, 2024
admin
Onyx Biotec IPO GMP grey market premium, review, Subscription, allotment, listing estimate @
Chanakyanipothi.com, a legacy of 31 Years.
India`s Oldest Investment & IPO website.
Most Trusted by Investors across India.
Table of Contents
Onyx Biotec listing Review
Will give detailed review on listing of this IPO
Onyx Biotec IPO allotment Link
For latest GMP, Click
Subscription status of Onyx Biotec IPO
|
Onyx Biotec Limited IPO Price Rs. 61 Lot 2000 shares, Rs. 29.34 Crore |
||||
| QIB | NII x | RII x | Total x | Applications |
| 32.49 | 602.86 | 118.26 | 198.00 | 103,947 (129.93x) |
| Amount wise bids recd. Rs. ? Crore | ||||
| Note: | ||||
What is the business of Onyx Biotec?
Onyx Pharmaceuticals: A Leading Supplier of Sterile Pharmaceutical Products
Onyx Pharmaceuticals has established itself as a trusted name in the healthcare sector, specializing in the production and supply of sterile pharmaceutical products. Over the years, the company has become a prominent supplier to major corporations, including some of the top pharmaceutical companies across India.
Commitment to Quality and Affordability
Onyx is committed to delivering high-quality products at affordable prices. Currently, the company manufactures Sterile Water for Injections and acts as a pharmaceutical contract manufacturer, providing a wide range of Dry Powder Injections and Dry Syrups for both the Indian and international markets. Our products are produced in compliance with global FDA standards and undergo rigorous testing at each stage of production to meet the highest international quality standards.
Industry-Leading Manufacturing and Regulatory Compliance
Its manufacturing process adheres to FDA best practices and is consistently tested to ensure compliance with international standards. The company’s facilities are FDA-certified and our products are regularly tested in-house and at FDA-approved laboratories to guarantee quality and safety.
It focuses on offering end-to-end product development and manufacturing solutions to its clients. Its services also include regulatory dossier preparation and filing for both Indian and global markets, helping its clients navigate the complex regulatory landscape.
State-of-the-Art Manufacturing Facilities
Onyx operates two state-of-the-art manufacturing units in Himachal Pradesh, strategically located to serve both domestic and international markets:
- Unit I: Bir Plassi, Near Sainimajra, Ropar, Nalagarh Road, District Solan – 174101, Himachal Pradesh, India.
- Unit II: Village Teliwala, P.O. Manjholi, Tehsil Nalagarh, District Solan – 174101, Himachal Pradesh, India.
Both facilities have been accredited by global regulatory bodies, including the World Health Organization Good Manufacturing Practice (WHO-GMP) certification.
Rigorous Audits and Inspections
Its manufacturing units undergo regular audits and inspections to ensure the highest standards of quality and compliance. In the financial years 2024, 2023, and 2022, the company’s facilities were subject to eight audits at Unit I and seven audits at Unit II, conducted by its clients. Additionally, it underwent three inspections by regulatory authorities, further reinforcing its commitment to maintaining industry-leading quality.
Key Clients and Partnerships
As of May 31, 2024, Onyx’s key clients include some of the most respected names in the pharmaceutical industry, such as:
- Hetero Healthcare Limited
- Mankind Pharma Limited
- Sun Pharmaceutical Industries Limited
- Aristo Pharmaceuticals Private Limited
- Macleods Pharmaceuticals Limited
- Mapra Laboratories Private Limited
- Axa Parenterals Limited
- FDC Limited
- Zuventus Healthcare Limited
- Akums Drugs and Pharmaceuticals Limited
- Reliance Life Sciences Limited
These partnerships are a testament to Onyx Pharmaceuticals’ growing reputation as a reliable supplier of high-quality sterile pharmaceutical products.
In conclusion, Onyx Pharmaceuticals continues to lead the way in the production and supply of sterile pharmaceutical products, driven by its commitment to quality, regulatory compliance, and customer satisfaction. With state-of-the-art manufacturing facilities, an extensive product range, and a strong portfolio of reputable clients, Onyx is well-positioned to continue its growth in the pharmaceutical sector both in India and globally.
Get more information about the company @ www.onyxbiotec.com
|
Onyx Biotec IPO Details |
|
| IPO opens on | 13 November 2024 |
| IPO closes on | 18 November 2024 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 4810,000 Shares / Rs 29.34 Crore |
| * Fresh Issue | 4810,000 Shares / Rs 29.34 Crore |
| * Offer for Sale – | – shares / Rs. – crore |
| Market Maker Portion | ? Shares |
| Net offer to Public | Shares/ Rs. Crore |
| Face Value per share | Rs. 10 |
| Price Band | Rs. 61 |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | 2000 Shares |
| Listing will at | NSE SME |
Shares offered in IPO |
||
| Shares | Rs. (Crore) | |
| QIB (50%) | ? | ? |
| NII (15%) | ? | ? |
| RII (35%) | ? | ? |
| Total Shares | ? | ? |
| Retail portion will be oversubscribed by |
? | |
| Forms | ||
| How much Shares to Apply in this IPO? | ||
| Min Retail Application | 2000 Shares | Rs.122000 |
| Min HNI Application | 4000 Shares | Rs.244000 |
Who are the Promoters of Onyx Biotec?
The Promoters of the company are Kantilal Jethva and Bhavin Jethwa.
What are the Objects of Onyx Biotec IPO?
The Offer comprises of fresh issue of shares
The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:
1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
3. Prepayment or repayment of all or a portion of certain loans availed by the Company; and
4. General Corporate Purposes.
Tentative timetable |
|
| IPO opens on | 13 November 2024 |
| IPO Closes on | 18 November 2024 |
| IPO Allotment on | 19 November 2024 |
| Refund Initiation | 20 November 2024 |
| Credit of Shares | 20 November 2024 |
| Listing on | 21 November 2024 |
| Registered Office of the Company Bir Plassi Near Sainimajraropar, Nalagarh Road, District Solan – 174 101, Himachal Pradesh, India |
| Who is the Lead Manager of this IPO? Horizon Management Private Limited |
|
Who is the Registrar to IPO? MAS SERVICES LIMITED |
Onyx Biotec IPO GMP grey market premium, review, Subscription, allotment, listing estimate
|
Onyx Biotec IPO Financial & Analytical Ratios |
||||
| Year | Total Income |
Net Profit |
EPS | RoNW |
| Rs.in Crore | Rs.in Crore | Rs. | % | |
| 2021-22 | 44.98 | 3.35 | 2.84 | |
| 2022-23 | 39.62 | 1.84 | 1.56 | |
| 2023-24 | 53.87 | 3.30 | 2.54 | |
| Book Value of the Share on 31.03.2024 |
Rs | 18.67 | ||
| BV of the Share at cap price after IPO |
Rs. | |||
| Offer Price/upper band | Rs. | 61 | ||
IPO
|
|
| Price/EPS of 23-24 | 24.01 |
| Price/BV Ratio | 3.26 |
| Price/BV after IPO | |
How Onyx Biotec IPO compares with the Peers?
There is no peer group listed company.
| As on date of DRHP | FV | Total | PE |
| Rs. | Income | Ratio of | |
| Rs. In Crore | |||
| Onyx Biotec | 10 | ||
| Suven Pharmachem | 1 | 1051 | 83.92 |
| JB Chemicals | 1 | 3484 | 53.63 |
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Onyx Biotec IPO Review
Onyx Pharmaceuticals: A Leading Supplier of Sterile Pharmaceutical Products
Onyx Pharmaceuticals has earned a strong reputation in the healthcare sector, specializing in the production and supply of sterile pharmaceutical products. Over the years, the company has become a prominent and trusted supplier to major pharmaceutical corporations, including some of the top-tier companies across India.
IPO Details: Size and Market Outlook
The IPO size is Rs. 29.34 crore, offering 4,810,000 shares. While the size is relatively modest compared to recent IPOs, the company’s strong business model and consistent growth trajectory make the IPO highly attractive. Given the company’s robust performance and promising outlook, the offering has the strong potential to be oversubscribed.
Strong Financial Performance and Reasonable Valuation
Onyx Pharmaceuticals has demonstrated impressive and consistent growth in both topline and bottomline over the past three years, further solidifying its position in the market. With its strong financial track record and solid fundamentals, the shares are offered at a reasonable valuation, making it an appealing investment opportunity.
A Worthwhile Investment Opportunity
Even in the absence of a grey market premium, the Onyx Pharmaceuticals IPO presents a compelling case for investment. With strong growth prospects and a proven business model, this IPO is a solid opportunity for investors looking to tap into the growing pharmaceutical sector.
+ from fundamental angle: Must Apply
+ from grey market angle: Not attractive
Quicklinks
Onyx Biotec IPO GMP today allotment, review?
Onyx Biotec IPO GMP grey market premium
Onyx Biotec IPO FAQs
What is Onyx Biotec IPO?
This is a SME IPO of 4810000 equity shares of the face value of Rs. 10 aggregating up to Rs.29.34 Crores. The issue is priced at Rs.61 per share. The minimum order quantity is 2000 Shares.
When will Onyx Biotec IPO subscription open?
Onyx Biotec IPO opens on November 13, 2024, and closes on November 18, 2024.
What is the lot size of Onyx Biotec IPO?
Onyx Biotec IPO lot size is 2000 Shares, and the minimum amount required is Rs.122000
How to apply for Onyx Biotec IPO?
You can apply in Onyx Biotec IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
When is Onyx Biotec IPO allotment?
The finalization of Basis of Allotment for Onyx Biotec IPO will be done on November 19, 2024, and the allotted shares will be credited to your demat account by November 20, 2024.
When is Onyx Biotec IPO listing date?
Onyx Biotec IPO listing date is November 21, 2024.
